Building On Outcomes With Isatuximab in Newly Diagnosed Myeloma

EP: 1.Reviewing the Approval Process of Teclistamab in Multiple Myeloma

EP: 2.Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP: 3.ASH 2023: The Most Relevant Multiple Myeloma Data Presented

EP: 4.ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma

EP: 5.Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma

EP: 6.FDA Approves Ide-Cel in Previously Treated Multiple Myeloma

EP: 7.FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy

EP: 8.Managing Cranial Nerve Impairment in Multiple Myeloma Following Cilta-cel

EP: 9.APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma

EP: 10.Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma

EP: 11.Daratumumab Retreatment Yields Sustained Response in R/R Multiple Myeloma

EP: 12.Step-Up Teclistamab Dosing Produces Responses in R/R Multiple Myeloma

Now Viewing

EP: 13.Building On Outcomes With Isatuximab in Newly Diagnosed Myeloma

EP: 14.Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

EP: 15.Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma

EP: 16.FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma

EP: 17.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm

EP: 18.MRD May Predict Improved Outcomes in Multiple Myeloma

EP: 19.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

EP: 20.Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma

EP: 21.Exploring GPRC5D as an Important Target for Multiple Myeloma

EP: 22.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

EP: 23.Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma

EP: 24.Optimizing AE Management Post CAR T-Cell Therapy in Multiple Myeloma

EP: 25.Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma

EP: 26.Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM

EP: 27.Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

EP: 28.Managing Toxicities Following BCMA-Directed Immunotherapy for Myeloma

EP: 29.Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

EP: 30.Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

EP: 31.Multiple Myeloma Experts Face Off on Sequencing Therapy Options

EP: 32.D-VRd Regimen Sustains MRD Response In Newly Diagnosed Multiple Myeloma Subgroup

EP: 33.Maintenance Teclistamab Yields Preliminary Activity in NDMM

EP: 34.General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

EP: 35.Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

EP: 36.Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM

EP: 37.Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma

EP: 38.Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma

EP: 39.CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma

EP: 40.Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma

In a conversation with CancerNetwork^® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,Thierry Facon, MD, spoke about building upon findings from the phase 3 IMROZ trial (NCT03319667), which demonstrated the efficacy of isatuximab-irfc (Sarclisa) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Isa-VRd) in patients with newly diagnosed transplant-ineligible multiple myeloma.

Although the Isa-VRd may become a standard of care for some elderly populations, Facon, a professor of hematology in the Department of Hematology at Lille University Hospital, discussed how next steps may involve exploring the potential benefits of this treatment in patients over 80 years old. Additionally, he highlighted how novel CAR T-cell strategies and bispecific antibodies may further improve upon the treatment outcomes observed with the Isa-VRd regimen.

At a median follow-up of 59.7 months, the median progression-free survival (PFS) was not reached with Isa-VRd vs 54.3 months in patients who received bortezomib, lenalidomide, and dexamethasone only (HR, 0.596; 98.5% CI, 0.406-0.876; P = .0005). Based on current trends in the PFS data, the median PFS with Isa-VRd is anticipated to be approximately 90 months.

Transcript:

This regimen will become a standard of care for a large proportion of elderly patients with myeloma. That being said, everything can be improved. In fact, we may want to look at patients over the age of 80 years so that we would be able to elaborate a regimen that will be suitable for very elderly patients. That's such an important question.

Then, we will have to implement, in different ways, new modalities for model mice. For example, CAR T strategies, bispecific antibodies, or new CELMoDs. You have several ways to improve on Isa-VRd. Also, considering that the median PFS will likely be over 80 months for the Isa-VRd arm, it will not be so easy. But of course, we must find something better.

Reference

Facon T, Dimopoulos MA, Leleu XP, et al. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). J Clin Oncol. 2024;42(suppl 16):7500. doi:10.1200/JCO.2024.42.16_suppl.7500